missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ ACVR1 Recombinant Rabbit Monoclonal Antibody (23GB3630), Invitrogen™

Description
Activin A receptor, type I (ACVR1) belongs to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. ACVR1 signals a specific transcriptional response in concert with activin type II receptors. The ACVR1 gene encodes activin A type I receptor, which signals a particular transcriptional response in concert with activin type II receptors. Mutations in ACVR1 have been linked to Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic disorder characterized by the formation of bone in muscles, tendons, and other connective tissues, as well as Epicanthus.
Specifications
Specifications
| Antigen | ACVR1 |
| Applications | Flow Cytometry, Western Blot, Immunocytochemistry |
| Classification | Recombinant Monoclonal |
| Clone | 23GB3630 |
| Concentration | 1.2 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 |
| Gene | ACVR1 |
| Gene Accession No. | P80201, Q04771 |
| Gene Alias | activin A receptor type 1; activin A receptor type I; activin A receptor, type 1; activin A receptor, type I; activin A receptor, type II-like kinase 2; activin receptor I precursor; activin receptor type I; Activin receptor type-1; activin receptor-like kinase 2; activin type I receptor; ACTRI; ActR-I; ActRIA; Acvr; ACVR1; ACVR1A; ACVRLK2; ALK2; Alk-2; ALK2-B; Alk8; ATVR1; D330013D15Rik; FOP; hydroxyalkyl-protein kinase; serine/threonine-protein kinase receptor; serine/threonine-protein kinase receptor R1; SKR1; TGF-B superfamily receptor type I; Tgfb1; Tsk7L; TSK-7L; TSRI; TSR-I; type I TGF B receptor |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?